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Osterix, a zinc-finger transcription factor, is specifically
expressed in osteoblasts and osteocytes of all developing bones.
Because no bone formation occurs in Osterix null mice, Osterix
is thought to be an essential regulator of osteoblast differentia-
tion. We report that bone morphogenetic protein-2 (BMP-2)
induces an increase in Osterix expression, which is mediated
through a homeodomain sequence located in the proximal
region of the Osterix promoter. Our results demonstrate that
induction of Dlx5 by BMP-2 mediates Osterix transcriptional
activation. First, BMP-2 induction of Dlx5 precedes the induction
of Osterix. Second, Dlx5 binds to the BMP-responsive homeodo-
main sequences both in vitro and in vivo. Third, Dlx5 overexpres-
sion and knock-down assays demonstrate its role in activating
Osterix expression in response to BMP-2. Furthermore, we show
thatDlx5 is anovel substrate forp38MAPK in vitroand in vivoand
that Ser-34 and Ser-217 are the sites phosphorylated by p38. Phos-
phorylationatSer-34/217 increases thetransactivationpotentialof
Dlx5. Thus, we propose that BMP activates expression of Osterix
through the induction of Dlx5 and its further transcriptional acti-
vation by p38-mediated phosphorylation.
Bone is a dynamic tissue that is constantly remodeled
throughout life. Bone remodeling activity is dependent on a
strict coupling mechanism of osteoclast resorption and new
matrix deposition by osteoblasts, and an imbalance between
these two activities leads to pathological states such as osteo-
porosis and osteosclerosis. Commitment to the osteoblast phe-
notype is ultimately controlled by a specific set of transcription
factors activated by signals and regulatory pathways. Among
them, bone morphogenetic protein (BMP)5 signaling has been
shown to be involved in bone regeneration and osteoblast dif-
ferentiation in vitro and in vivo (1–3).
BMP target genes include a growing number of tissue-deter-
mining transcription factors that promote differentiation of
mesenchymal precursors toward the osseous cell phenotypes.
For instance, osteogenic induction of bone marrow mesenchy-
mal stem cells or premyogenic C2C12 cells has identified sev-
eral types of transcription factors such as Id1, several homeodo-
main proteins, ATF4, the runt homology domain factor Runx2
(Cbfa1) and Osterix (Osx) (for review, see Refs. 4–6). Runx2
and Osx have been widely accepted as master osteogenic fac-
tors since neither Cbfa1 nor Osx null mice form mature osteo-
blasts (7, 8). Nakashima et al. (8) identified Osx as a zinc-finger
SP1 family member induced by BMP-2 in C2C12 cells that is
specifically expressed in osteoblasts and osteocytes of all devel-
oping bones. In Osx-null mice, no bone formation takes place,
although Runx2 is expressed, suggesting that Osx acts down-
stream of Runx2 during bone development (8). It has been sug-
gested that Runx2 would function from the commitment step
to the point where osteochondroprogenitors appear, whereas
Osx would have a role in the segregation of osteoblasts from
osteochondroprogenitors (5). Supporting these differential
regulatory pathways for Runx2 and Osx, it has been suggested
that Osx promotes proliferation of progenitor cells, whereas
Runx2 has an antiproliferative effect (9, 10). In addition,
NFATc1 forms a complex with Osx and activates Osx-depend-
ent collagen 1 promoter activity, whereas it does not activate
Runx2-dependent transcription (11).
Different homeodomain-containing transcription factors
have been implicated in chondrogenesis and osteogenesis. For
instance, two isoforms of Prx1, called Prx1A and -B, are critical
for cartilage, bone, and tooth development (12–15). Dlx3, -5,
and -6 are transcription factors that belong to the distal-less,
homeodomain-containing family of transcription factors.
Their genes are arranged in tightly linked bigene pairs in the
genome and are co-expressed in developing bones (16). Dlx5-
null mice have craniofacial abnormalities with a delayed cranial
ossification and abnormal osteogenesis (17, 18). Inactivation of
both Dlx5 and Dlx6 results in skeletal defects that are consid-
erably more severe, suggesting that they have redundant func-
tions and are involved in endochondral ossification as well (19).
Forced expression of Dlx5 or Dlx3 in cell culture leads to
increased expression of osteogenic markers such as osteocal-
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cin, Runx2, and alkaline phosphatase (20–24). These home-
odomain transcription factors exhibit distinct temporal
expression profiles during osteoblast differentiation, with
Dlx3 expressed in osteoprogenitors and Dlx5 expressed in
more mature osteoblasts.
Runx2 and Osx transcription is stimulated by BMP treat-
ment in vitro (8, 25). Pretreatment with cycloheximide blocks
these inductions, suggesting that either Runx2 or Osx are not
direct targets of the BMP signaling cascade but require the
expression of newly synthesized intermediates (26, 27). In
contrast, BMP-2-induced Dlx5 transcription is unaffected
by cycloheximide pretreatment (26). Interestingly, although
expression of Osx in vivo requires Runx2, BMP-2 is still able to
stimulate alkaline phosphatase activity and Osx expression in
Runx2 deficient cells, whereas they were completely abrogated
by antisense against Dlx5 (27).
Although these data suggest that Dlx5 is involved in BMP-
induced Osx expression, little is known about the mechanism
for activation of Osx expression in response to BMP signaling.
In this study, we identified a homeodomain regulatory se-
quence as the BMP-2-responsive region in the Osx promoter.
The Dlx5 temporal expression pattern and binding to the
responsive region as well as overexpression and knock-down of
Dlx5 demonstrates its role in activating Osx expression in
response to BMP-2. Furthermore, we show that Dlx5 is a novel
substrate for p38MAPK in vitro and in vivo and that Ser-34 and
Ser-217 are the regulatory sites phosphorylated by p38. The
transactivation potential of Dlx5 was increased by p38 phos-
phorylation, resulting in an increased expression of Osx. We
propose a regulatory network where BMP activates expression
of Osx through the induction of the immediate early gene Dlx5
and its further transcriptional activation by p38-mediated
phosphorylation.
EXPERIMENTAL PROCEDURES
Plasmids, Reagents, and Antibodies—The murine Osterix
promoter from1812 to93 was obtained by PCR and cloned
in the pGL2basic vector. Mutants were generated by cutting
with SpeI, SmaI, SacI, or Kpn21, respectively. Annealed oligo-
nucleotides encoding from either the 114 to 51 wild type
sequence or the indicated mutations were cloned in the mini-
mal promoter of c-fos promoter (28). cDNA encodingDlx5was
provided by Dr. Watanabe (National Institutes for Longevity
Sciences, Japan) and subcloned into pGEX and pcDNA3.1His
expression vectors. HisDlx5 was used as a parental plasmid to
generate the phosphorylation mutants using PCR approaches.
Dlx3, Prx1A, and Prx1B expression vectors were provided by
Drs. M. Morasso (NIH, Bethesda, MD) and M. Kern (Medical
University of South Carolina), respectively. Activated MKK6
expression vector and recombinant p38 were provided by Dra.
P. Muñoz-Canoves (CRG, Barcelona, Spain). Expression vec-
tors encoding p300 and histone acetyltransferase (HAT)
mutant were provided by Dr. M. Martinez-Balbas (CID, Barce-
lona, Spain). BMP-2 was a generous gift from Wyeth (Cam-
bridge, MA). SB203580 (Calbiochem) was used at a final con-
centration of 10 M. Antibodies against FLAG (M2 antibody
F3165) (Sigma), His (His antibody 27–4710) (Amersham Bio-
sciences), -tubulin (Sigma), and phospho-p38 (Cell Signaling,
Beverly, MA) were used at 1:1000. Antibodies against Dlx5
C-20 (sc-18152) and Y-20 (sc-18151) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) were used at 1:500.
Cell Culture and Transfection—C2C12 and HEK-293 cell
lines were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 15% fetal bovine serum, glutamine, pyru-
vate, and antibiotics. To induce differentiation, the medium
was replaced by Dulbecco’s modified Eagle’s medium without
serum and BMP-2 at a final concentration of 2 nM. C2C12 cells
were transiently transfected using Lipofectamine 2000 (Invitro-
gen) or FuGENE 6 (Roche Applied Science). HEK-293 cells
were transiently transfected using FuGENE 6.
RT-qPCR Analysis—Total RNA was isolated from C2C12
cells using the Ultraspec RNA Isolation System (Biotecx, Hous-
ton, TX). 5 g of total RNA were reverse-transcribed using a
Ready-to-Go First Strand kit (Amersham Biosciences) and
oligo-dT as a primer. Quantitative PCRs were carried out using
ABI Prism 7900HT Fast Real-Time PCR System and a Taqman
5-nuclease probe method (Applied Biosystems, Foster City,
CA). All transcripts were normalized to GAPDH, and transfec-
tion efficiency was assessed by green fluorescent protein
expression.
Reporter Assays—C2C12 cells were transfected overnight.
The next day cells were split before reaching confluence and
treated with BMP-2 for 16–20 h. Luciferase activities were
quantified using the luciferase assay system (Promega, Madi-
son, WI). Luciferase values were normalized using -galacto-
sidase activity measured with the luminescent -galactosidase
detection kit II (Clontech, Palo Alto, CA).
Electrophoretic Mobility Shift Assays—100 ng of purified
GST-Dlx5 fusion proteins and 1 l of 32P-labeled probes were
incubated in 40 mM Tris-HCl, pH 7.5, 10% glycerol, 10%
Sacarose, 5 mM MgCl2, 70 mM KCl, 0.1 mM EDTA, 1 mM
dithiothreitol, and 1 g of poly(dI/dC) for 20 min at room
temperature. Protein-DNA complexes were resolved on a 5%
nondenaturating polyacrylamide gel.
Biotinylated Oligonucleotide Precipitation Assays—HEK-
293 cells were transfected and 48 h later were lysed as
described previously (28). Biotinylated oligonucleotides
encoding the 114 to 51 fragment of the Osterix promoter
were incubated overnight with cell extracts in presence of 2 g
of poly(dI/dC) and collected with streptavidin-agarose beads
(Pierce).
RNA-mediated Interference Assays—To knock down Dlx5
expression, two siRNA oligonucleotides against Dlx5 mRNA
were purchased from Dharmacon (Lafayette, CO): ON-TAR-
GETplus J-041405-09 (J9) and J-041405-10 (J10). As a control,
the non-targeting oligonucleotide ON-TARGETplus siCON-
TROL non-targeting siRNA D-001810-01 was transfected
under the same conditions. C2C12 cells at 95% of confluence
were transfected by using Lipofectamine 2000 (Invitrogen).
After 16 h newmediumwith 15% fetal bovine serumwas added
to recover cells, and 8 h later cells were depleted overnight and
then treated with or without BMP-2.
Immunofluorescence Assay—24 h after transfection, C2C12
cells were fixed in 3% paraformaldehyde for 30 min, permeabi-
lized in 0.2% Triton X-100, and blocked with 3% bovine serum
albumin in Tris-buffered saline. Cells were stained with mouse
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anti-FLAG (Sigma) at 1:400 dilution followed by goat anti-
mouse IgG conjugated with Alexa 488 at 1:2000. Labeling was
detected using a Leica TCS SL inverted laser scanning confocal
microscope.
Metabolic Labeling—Labelingwith [35S]methioninewas per-
formed as previously described (29) using HEK-293 cells
expressing the indicated constructs followed by immunopre-
cipitation of labeled protein with anti-Dlx5 (Y-20 plus C-20,
Santa Cruz Biotechnology).
In Vitro Phosphorylation by p38 MAPK—1 g of GST-p38
MAPK was activated by incubation with MBP-MKK6-DD (5:1
ratio) at 30 °C for 20min in a buffer containing 50mMTris-HCl,
pH 7.5, 10 mM MgCl2, 2 mM dithiothreitol, and 200 M ATP.
Activated p38 (50 ng) was incubated with 1 g of recombinant
Dlx5 in the same buffer supplemented with 1 M ATP and 3
pmol of [-32P]ATP at 30 °C for 20 min.
Chromatin Immunoprecipita-
tion—C2C12 cells were transfected
by FuGENE 6 with the indicated
constructs. Chromatin immuno-
precipitation (ChIP) assays were
performed using the ChIP assay
kit (Upstate Biotechnology, Lake
Placid, NY) according to the manu-
facturer’s instructions but repeating
all the washes twice. Antibodies
used were anti-FLAG M2 (Sigma),
anti-p300 (N-15, Santa Cruz Bio-
technology), anti-acetylhistone H3,
anti-RNA polymerase II, and con-
trol IgG (Upstate).
RESULTS
Osterix Expression Is Stimulated
byBMP-2 inC2C12Cells—Previous
studies had shown that Osx mRNA
levels increase after BMP-2 addition
in mesenchymal cell types, includ-
ing primary osteoblasts, mesenchy-
mal stem cells, and C2C12 cells (8,
27, 30, 31). To assess the temporal
pattern of this response, we evalu-
ated Osx mRNA levels in C2C12
cells at different time points after
BMP-2 addition.Osxwas not signif-
icantly expressed in undifferentiated
C2C12 cells; however, upon BMP-2
addition, Osx mRNA levels were
strongly increased (Fig. 1A). Osx
expressionwas initiallydetectedat2h
and reached a maximum expression
8–16 h after BMP addition. This late
inductionofOsxmRNAsuggests that
Osx is an indirect target of BMP sig-
naling, which is in agreement with
previous data which had indicated
that induction of Osx required new
protein synthesis (27).
A Homeobox Element Present in the Proximal Promoter
Region Is the BMP-2-responsive Element—Previous work had
shown that both the human and mouse Osx mRNA have two
isoforms arising from two alternative promoters. These include
a highly abundant form arising from the most proximal tran-
scription start site and a minor form that is poorly transcribed
(32–34). Our analysis indicates that BMP-2 activates the
expression of the Osx mRNA form arising from this proximal
transcription start site (Fig. 1A). This proximal TATA-less pro-
moter contains a consensus Inr sequence at the transcription
start site PyPyA(1)NT/APyPy (35) and a cytosine-rich region
between the 51 and 25 nucleotide. To define the BMP-2
responsive elements in the Osx promoter, we isolated this
upstream regulatory sequence of the murine Osx gene. Using a
reporter construct in C2C12 cells, we observed 3-fold activa-
tion with 2 nM BMP-2 (Fig. 1B).
FIGURE 1. Transcriptional activation of Osx expression by BMP-2. A, confluent C2C12 cells were depleted of
serum overnight and treated with BMP-2 2 nM for the indicated times. Osx mRNA was measured by RT-qPCR,
normalized to GAPDH, and plotted as relative expression to time 0  S.E. of six independent experiments. B and
C, when confluent, transfected C2C12 cells were treated with BMP-2 2 nM in serum-depleted media. 16 –20 h
later, luciferase activity was measured and normalized against -galactosidase activity. Basal activities are
shown as relative units compared with the activity of the 1812/93 reporter (B) or the 114/93 reporter
construct (C). BMP-2 induction of luciferase activities are expressed as -fold induction  S.E. of five to seven
independent experiments. wt, wild type.
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Then we used reporter assays to analyze serial deletions of
the 1.9-kilobase promoter. The deletion of sequences from
1812 to 114 produced only slight decreases in BMP-2
reporter induction. However, further removal of a short region
(114 to 51) resulted in a complete loss of BMP-2 respon-
siveness (Fig. 1B). To test whether this region alone has the
ability to render responsiveness to
BMP-2, we assayed the responses of
a construct containing this 63-bp
region (comprising from 114 to
51) upstream of a heterologous
c-fos minimal promoter. Whereas
theminimal c-fos promoter showed
no response at all to BMP-2, BMP-2
activated the construct bearing
the enhancer (indicated as wt in
Fig. 1C).
Homology analysis showed that
the 114/51 region is almost
totally conserved among vertebrate
species available in databases.
Hence, this 63-bp region was ana-
lyzed with MatinspectorTM (Geno-
matix), and three putative tran-
scription factor binding sites were
detected; a GC-rich region similar
to a BMP responsive Smad binding
element (28, 36), a palindromic
homeobox binding site (TAATTA),
and a CAGAC box. Mutation of the
individual enhancer elements in the
reporter construct followed by
luciferase analysis showed that the
homeobox mutant lost BMP-2
responsiveness, whereas no signifi-
cant effects were observed for the
mutated GC-rich construct, and
only a slight decrease in the basal
levels but not in the induction was
observed in the CAGAC box muta-
tion (Fig. 1C).
Dlx5 Interacts Directly with the
Homeobox Region in the Osterix
Promoter and Mediates BMP-2
induced Osx Expression—Because
the TAATTA sequence is a canoni-
cal homeodomain binding site, we
tested different homeobox tran-
scription factors involved in osteo-
genesis with the ability to bind the
TAATTA sequence as putative acti-
vators of the Osx promoter. Neither
Prx1A, Prx1B, nor Dlx3 showed
significant effects, whereas Dlx5
showed more than a 3-fold induc-
tion of the promoter (Fig. 2A). Dlx5
failed to induce transcriptional acti-
vation of the TAATTA reporter
construct (data not shown). Thus, we analyzed whether Dlx5
bound to the BMP-responsive elements of Osx promoter using
two complementary approaches. Electrophoretic mobility shift
assays were carried out incubating GST-Dlx5 protein with
probes corresponding to the wild type or the mutated minimal
responsive region. GST-Dlx5 was able to bind all the probes
FIGURE 2. Dlx5 binds and activates the Osx promoter. A, the indicated homeobox transcription factors were
co-transfected with the minimal Osx promoter reporter. Luciferase activity was measured and normalized as
above. The values, relative to cells transfected with the reporter alone, are expressed as the mean  S.E. of four
independent experiments. Expression levels of the different transcription factors were measured by immuno-
blotting. Tubulin immunodetection is also shown as a protein loading control. B, electrophoretic mobility shift
assays were performed using the indicated 32P-labeled probes containing either the 114/51 wt sequence
or the indicated (GC-rich, TAATTA, or CAGAC) mutations. wt, wild type. C, the wild type, TAATTA, and CAGAC
double-stranded biotinylated oligonucleotides were incubated with equal aliquots of extracts from cells
expressing FLAG-tagged Dlx5 or green fluorescent protein as control. DNA-protein complexes purified with
streptavidin-agarose were analyzed by immunoblotting using anti-FLAG antibody. D and E, confluent C2C12
cells were depleted of serum overnight and treated with 2 nM BMP-2 for the indicated times. D, Osx and Dlx5
mRNAs were measured by RT-qPCR, normalized to GAPDH expression, and plotted as relative expression to
time 0  S.E. of four independent experiments. E, Osx and Dlx5 protein levels were measured by immunoblot-
ting. Quantification was performed using the Bio-Rad Molecular Imager software and normalized to tubulin
expression. The values are plotted as relative expression to time zero  S.E. of four independent experiments.
F, confluent MC3T3-E1 cells were depleted of serum overnight and treated with 2 nM BMP-2 for the indicated
times. Osx and Dlx5 mRNAs were measured by RT-qPCR, normalized to GAPDH expression, and plotted as
relative expression to time 0  S.E. of three independent experiments.
BMP-2 Control of Osterix Expression through Dlx5
FEBRUARY 15, 2008 • VOLUME 283 • NUMBER 7 JOURNAL OF BIOLOGICAL CHEMISTRY 3819
except that which contained a mutated homeobox (Fig. 2B).
The appearance of the shifted band was abolished by incuba-
tion with antibodies against Dlx5, further confirming that the
shifted band was indeed Dlx5 (supplemental Fig. 1). Similarly,
oligonucleotide pulldown assays of HEK-293 cells overexpress-
ingDlx5 showedbinding ofDlx5 to the homeoboxDNAbut not
when the homeobox sequence was mutated (Fig. 2C).
Dlx5 has been shown to be induced in C2C12 cells in
response to BMP-2 through the activation of the Smad signal-
ing pathway (6, 26). We analyzed the temporal pattern of
expression of both genes to assess whether Dlx5 could act
upstream of Osterix. Dlx5 mRNA was induced 1–2 h after
BMP-2 addition and increased steadily thereafter. Osterix
mRNA levels were also increased showing a delayed profile of
induction compared with that of Dlx5mRNA (Fig. 2D). Similar
expression profiles were obtained when the protein levels of
Dlx5 and Osx were analyzed byWestern blot analysis (Fig. 2E).
We further analyzed the pattern of expression of both Dlx5 and
Osx in the osteoblast cell line MC3T3-E1. Similarly to mesen-
chymal C2C12 cells, BMP-2 induces both Dlx5 andOsxmRNA
expression, and the Dlx5 mRNA induction also preceded that
of Osx (Fig. 2F). Altogether, these data show that BMP-2
induces both Dlx5 and Osx expression in different mesenchy-
mal cell lines and indicates that the induction ofDlx5 by BMP-2
precedes that of Osx.
To directly address a functional role of Dlx5 in Osx expres-
sion regulation, we tested two different siRNAs against Dlx5 (J9
and J10) in C2C12 cells. BMP-2-induced Dlx5 mRNA and pro-
tein expressionwere decreased comparedwith cells transfected
with a scrambled siRNA (non-target control (NTC)) (Fig. 3, A
and B). BMP-2-induced Osx expression was decreased by the
two siRNAs (55% by J9 and 35% by J10 at the mRNA level and
35%by J9 and 20%by J10 at the protein level).Moreover,we also
co-transfectedC2C12 cells with J9 siRNAagainstDlx5 together
with the minimal responsive Osx reporter. J9 siRNA decreased
both basal andBMP-2mediated responses (Fig. 3C). These data
are also in agreement with previous data using antisense con-
FIGURE 3. Dlx5 is necessary for BMP-2 induction of Osx. A and B, C2C12
cells were transfected with 200 pmol of siRNAs (J9 and J10) targeted against
Dlx5 or a scrambled siRNA (non-target control (NTC)). 24 h after transfection
cells were depleted of serum overnight and treated with BMP-2 2 nM for 8 h.
A, Dlx5 and Osx mRNA were measured by RT-qPCR, normalized to GAPDH,
and expressed as relative expression  S.E. of five independent experiments.
B, Osx and Dlx5 protein levels were measured by immunoblotting. Quantifi-
cation was performed using the Bio-Rad Molecular Imager software and nor-
malized to tubulin expression. The values are plotted as relative expression 
S.E. of four independent experiments. C, C2C12 cells were transfected with
the minimal Osx promoter reporter construct together with 200 pmol of a
siRNA targeted against Dlx5 (J9) or an scrambled siRNA (NTC). 24 h later cells
were serum-deprived and treated with BMP-2. Luciferase activity was meas-
ured as above. Values represent the average of four independent experi-
ments  S.E. after normalization by -galactosidase activity.
FIGURE 4. Dlx5 activates Osx expression. A, transfected C2C12 cells were
grown to confluence, serum-starved, and treated with BMP-2 for 16 –20h.
Luciferase activities are expressed as the mean  S.E. for triplicates from six
independent experiments. B, transfected C2C12 cells were grown to conflu-
ence, serum-starved overnight, and treated with BMP-2 for 8 h. Relative val-
ues of Osx mRNA expression were obtained by RT-qPCR and expressed as the
mean  S.E. from four independent experiments after normalization by
GAPDH expression.
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structs against Dlx5 (27). Then we also analyzed the functional
effects of up-regulation of Dlx5 expression on the minimal Osx
reporter activity assays and endogenous Osx gene expression.
Dlx5 overexpression up-regulated transcription of theminimal
Osx reporter construct as well as expression of the endogenous
Osx gene analyzed by RT-qPCR (Fig. 4). We consistently
observed that in cells subjected to transfection procedures,
BMP-2 showed a lower ability to stimulate Osx expression.
More interestingly, in both experimental assays BMP-2 pro-
moted an additive effect to Dlx5-overexpressing C2C12 cells.
These data indicate that, in addition to the induction of Dlx5
expression, BMP-2 activates additional pathways that result in
further Osx transcriptional activation.
Dlx5 Is Phosphorylated by p38—The fact that a CAGAC site
is also present in theminimal BMP-responsive promoter led us
to investigate whether direct binding of Smads was also
involved in Osx transcription. However, neither deletion of the
CAGAC sequence (Fig. 1C) nor overexpression of Smad1 or
Smad4 (data not shown) significantly modify BMP-2 respon-
siveness of the minimal Osx reporter. Alternatively, it has been
shown that BMP-2 activates Smad-independent pathways (37).
For instance, activation of p38 MAPK by BMP-2 has been
shown to be relevant in the osteogenic effects of this cytokine
(38–40). Furthermore, the inhibition of the p38 pathway
strongly inhibits Osx expression induced by BMP-2, insulin-
like growth factor-I, or mechanical stress (41–43). Thus, we
analyzed whether Dlx5 could be a target of the p38 pathway.
With this objective we used a constitutive active form ofMKK6
that phosphorylates and activates p38 and analyzed cell extracts
from C2C12 cells expressing Dlx5. Dlx5 appeared as two bands
in the presence of MKK6 compared with the single band of the
extracts from cells expressing Dlx5 alone (Fig. 5A). Moreover,
pretreatment of C2C12 cells with SB203580, a potent and selec-
tive inhibitor of p38 MAPK, abrogated the retarded band, sug-
gesting that this band is due to p38 phosphorylation. To con-
firm these results, immunoprecipitates of 35S-labeled Dlx5
from cells co-transfected with Dlx5 andMKK6 were incubated
with alkaline phosphatase. Phosphatase treatment converted
the major upper forms of Dlx5 into
the lower ones, indicating that the
retarded band arose from phospho-
rylation events (Fig. 5B). Then we
examined whether Dlx5 was a direct
substrate of p38 by in vitro phospho-
rylation assays using recombinant
proteins.Dlx5was phosphorylated by
p38 (Fig. 5C). Next, we examined
whether the activationofp38 induced
byBMP-2was sufficient for the phos-
phorylation of endogenous Dlx5. In
agreementwith previous reports (40),
treatment of C2C12 cells with
BMP-2 induced activation of p38
(Fig. 5D). Endogenous Dlx5 appeared
as two bands, and BMP-2 treatment
increased both the total amount of
Dlx5 (in agreement with the RT-
qPCR data) and the ratio between
retarded versus highermobilityDlx5 bands (from a ratio of 0.95
0.10 at 0 h to a ratio of 1.4  0.2 at 2 h). Taken together, these
results demonstrate that p38 is able todirectly phosphorylateDlx5
in vivo and in vitro.
p38 Phosphorylation Enhances Dlx5 Transcriptional Activity—
To investigate whether this phosphorylation has a functional
effect on Dlx5 transcriptional activity, C2C12 cells were co-
transfected with the Osx minimal promoter construct with
Dlx5 andMKK6 in the presence or absence of BMP-2 (Fig. 6A).
Reporter activity was increased in cells co-transfected with
MKK6 alone in a SB-dependentmanner (up to 2-fold induction
compared with control cells) similar to the induction of cells
treated with BMP-2. Furthermore, expression of MKK6 was
able to further increase the reporter responsiveness to Dlx5 in a
SB-dependent manner (up to 2-fold increase), suggesting a
functional role for p38-induced Dlx5 phosphorylation. To con-
firm the functional effect of phosphorylation by p38, we also
analyzed whether MKK6-activated Dlx5 may enhance the
endogenous Osx expression by RT-qPCR. Endogenous Osx
expression increased when C2C12 cells were transfected with
MKK6 (up to 4-fold with respect to control cells) in a SB-de-
pendent manner (Fig. 6B). Furthermore, expression of MKK6
was able to cooperate with Dlx5, further increasing the level
of Osx expression, whereas SB203580 treatment abolished
this effect. These data further support the hypothesis of an
enhanced Dlx5 transcriptional activity induced by p38
phosphorylation.
To examine the mechanisms by which phosphorylation of
Dlx5 enhances its transcriptional activity, we first analyzed
Dlx5 subcellular localization. Immunofluorescence analysis in
C2C12 cells transfected with Dlx5 showed that Dlx5 has
nuclear localization (Fig. 6C). Next, we analyzed whether
MKK6 changed the Dlx5 protein turnover. C2C12 cells were
treated with the protein synthesis inhibitor cycloheximide for
different times. The degradation pattern of Dlx5 was mostly
similar either in the presence or absence of MKK6 (Fig. 6D).
Electrophoreticmobility shift assays indicated that the ability of
Dlx5 to bind to its responsive probe in Osx promoter was not
FIGURE 5. Dlx5 is phosphorylated by p38. A, HEK-293 cells were transfected with the indicated constructs.
After 24 h of transfection, cells were treated with SB203580 (SB) for 3 h. Dlx5 and tubulin were detected by
immunoblotting. B, HEK-293 cells transfected with the indicated constructs were labeled with [35S]methionine
for 3 h as described under “Experimental Procedures.” Aliquots of immunoprecipitated Dlx5 were incubated
with alkaline phosphatase (ALP) for 1 h and visualized by SDS-PAGE and autoradiography. C, GST-Dlx5 fusion
protein was incubated with activated p38 MAPK in the presence of -[32P]ATP and visualized by SDS-PAGE and
autoradiography. D, cell extracts from C2C12 cells treated with BMP-2 for 0, 2, and 4 h were analyzed by
immunoblotting with the indicated antibodies. p-, phosphorylated.
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modified by phosphorylation in vitro with activated p38 (Fig.
6E). To investigateDlx5 binding in theOsterix promoter in vivo
we performed chromatin immunoprecipitation assays in
C2C12 cells transfected with Dlx5 with or without MKK6. As
shown in Fig. 7A, Dlx5 boundOsterix promoter in vivo. Binding
of Dlx5 to the promoter is enough to recruit p300, RNA poly-
merase II, and acetylated histone H3. To further confirm the
involvement of p300 in activation of Osx expression, we ana-
lyzed the effects of p300 in the activation of the minimal Osx
reporter construct. p300 expression was able to cooperate with
Dlx5 in the transcriptional activation of the Osx reporter,
whereas a mutated form of p300 devoid of histone acetyl-
transferase activity was unable to further increase the Dlx5
activation (Fig. 7B).
Dlx5 Is Phosphorylated at Ser-34 and Ser-217 by p38 MAPK—
Sequence analysis of Dlx5 revealed four distinct serines corre-
sponding to consensus sites for MAPK phosphorylation con-
served in Dlx5 orthologs. We generated site-directed mutants
corresponding to these sites where Ser was changed to Ala.
Expression ofMKK6 induced the appearance of retarded phos-
phorylated bands when co-trans-
fected with either wild type or the
mutant forms S206A and S220A
(supplemental Fig. 2). MKK6, when
co-transfected with the S34A or the
S217A forms, only induced partially
retarded bands, whereas the double
mutant S34A/S217A lost p38-
dependent phosphorylation and was
detected exclusively as a high-migrat-
ing band irrespective of expression of
MKK6 (Fig. 8A). Then we tested
whether activated p38 MAPK could
phosphorylate Dlx5(S34A/S217A) in
vitro. As expected, only the wild type
form of Dlx5, but not Dlx5(S34A/
S217A), was 32P-labeled (Fig. 8B).
These results confirm phosphoryla-
tion of Dlx5 by p38 at Ser-34 and Ser-
217 in vivo and in vitro.
Thenwe assessed the relevance of
Ser-34 and Ser-217 phosphoryla-
tion on transcriptional activity of
Dlx5 in the Osx minimal reporter
construct. Expression of the differ-
ent constructs showed no signifi-
cant differences with respect to the
wild type when expressed alone.
However, S34A and S34A/S217A
were partially refractory to the
cooperative transcriptional effects
induced by co-transfection of MKK6
comparedwith either thewild type or
the S217A mutant (Fig. 8C). The dif-
ferentmutants were also analyzed for
activation by BMP-2 (Fig. 8D).
Whereas induction of the reporter
activity by mutant forms of Dlx5 in
the absence of BMP-2 was similar to the wild type, induction of
luciferase activity by BMP-2 in S34A- and S34A/S217A-trans-
fected cells was significantly reduced. Finally, we analyzed the
functional effects of expression of the Dlx5 Ser-34/Ser-217
mutant on expression of endogenous Osx gene. Cells overex-
pressing the Ser-34/Ser-217mutant were partially refractory to
the stimulatory effects of BMP-2 (Fig. 8E). Thus, phosphoryla-
tion of Ser-34 and Ser-217 seems to be crucial for the regulation
of Dlx5 transcriptional activity by p38.
DISCUSSION
Osx expression is limited to some types of cells of the mes-
enchymal lineage such as osteoblasts, chondrocytes, and osteo-
sarcoma cell lines (33). Furthermore, Osx expression is not
detected before E13 in mice and is more restricted to osteo-
blasts than Runx2 (8). Analysis of the promoter sequence iden-
tified binding sites for transcription factors involved in osteo-
blast differentiation such as Runx2, vitamin D receptor
homeobox family, or NF-B. For instance, the Runx2 and NF-B
siteshavebeen shown tobe functional in regulating the expression
FIGURE 6. p38 phosphorylation enhances Dlx5 transcriptional activity. A, C2C12 cells were co-transfected
with the minimal Osx reporter construct and combinations of Dlx5 and activated MKK6 expression vectors.
Cells were grown to confluence and treated with SB203580 and/or BMP-2 for 20 h. Luciferase activities are
expressed as the mean  S.E. of triplicates from four independent experiments. B, C2C12 cells were
transfected with the indicated constructs. Cells were grown to confluence and treated with SB203580 for
8 h. Relative values of Osx mRNA expression were obtained by RT-qPCR analysis and are expressed as the
mean  S.E. from six independent experiments after normalization by GAPDH expression. C, subcellular
localization of Dlx5 in C2C12 cells was analyzed by immunofluorescence with anti-FLAG antibody in cells
transiently transfected with FLAG-tagged Dlx5 expression vector. Bar, 20 m. D, HEK-293 cells were
transfected with the indicated constructs. After 24 h cells were treated with cycloheximide for the indi-
cated times. Dlx5 was detected by immunoblotting. E, GST-Dlx5 was incubated with activated p38 MAPK.
Aliquots were subjected to electrophoretic mobility shift assay with the minimal Osx promoter probe or
immunoblotted (WB) against Dlx5 antibody.
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of Osx, further confirming the genetic evidence that Runx2
expression is required for proper Osx expression (32, 34). Our
deletion analysis also indicated that in C2C12 cells, the deletion
of the NF-B binding site decreased basal reporter activity.
However, BMP responsiveness, restricted to the region
between 114 and 51, does not contain these sites. Muta-
tional analysis of this region identified a homeodomain binding
site as being particularly important for BMP-2 responses.
Although we cannot rule out the requirement of additional
transcription factors, several evidences strongly suggest that
Dlx5 binding activity play an essential role in mediating these
effects. First, the induction of Osx mRNA by BMP-2 requires
6–8 h, whereas the induction of Id1, a known direct Smad-
responsive gene, only requires 1 h (28). Second, the temporal
expression pattern after activation by BMP-2 (Fig. 3) or in other
models of differentiation of osteoblast precursors indicate that
the expression of Dlx5 always precedes that of Osx and other
markers of terminal differentiation such as osteocalcin or alka-
line phosphatase (21). Third, chromatin immunoprecipitation
assays indicate Dlx5 binding to the Osx proximal promoter
region in vivo, and recombinant Dlx5 binds specifically to that
site in vitro. Finally, the overexpression of Dlx5 enhances,
whereas siRNAs against Dlx5 reduce, both basal and BMP-in-
duced transcriptional responses of either reporter or endoge-
nous Osx mRNA expression. These data are in agreement
with previous results indicating that Dlx5 is an immediate
early BMP-responsive gene insensitive to the addition of
cycloheximide, whereas the induction of Osx is absolutely
sensitive to this protein synthesis inhibitor (26, 27, 44).
BMP-2 is still able to stimulate Osx expression in cells with
targeted deletion of Runx2, whereas Osx expression is
reduced in cells treated with antisense or siRNAs against
Dlx5 (Ref. 27 and present work). Furthermore, overexpres-
sion of dominant negative Runx2 constructs did not block
BMP-2-stimulated Osx mRNA expression (27, 30). Alto-
gether, our data further support the idea that BMP-depend-
ent induction of Osx expression depends on Dlx5 and can
occur independently of the changes of Runx2 expression.
Two major Runx2 isoforms are expressed from alternative
promoter usage. Expression of Runx2-II, a bone-specific iso-
form, co-localizes with BMP-2 and Dlx5 during calvarial bone
development. Expression of this isoform is specifically regu-
lated by BMP-2 through regulation of Dlx5 function (21, 23).
Thus, as suggested in other developmental and differentiation
processes, a feed-forward transcriptional mechanism seems to
operate in the BMP-induced osteoblast differentiation. Dlx5,
acting as an early gene induced by BMP-2, induces direct tran-
scriptional activation of at least two other osteoblast master
FIGURE 7. Role of p300 in Dlx5 activation of Osx promoter. A, diagram
showing the location of the primers used to amplify Osx promoter (284 to
77) in the chromatin immunoprecipitation analysis. B, C2C12 cells were
transfected with the indicated constructs. Chromatin immunoprecipitation
analysis was performed by incubating DNA-protein complexes with antibod-
ies against FLAG, p300, acetylhistone 3 (AcH3), RNA polymerase II (pol II), and
IgG as a negative control. C, either p300 or a HAT (histone acetyltransferase)
mutant, which loses the histone acetyltransferase domain, were co-trans-
fected with Dlx5 and the minimal Osx reporter. Luciferase experiments were
performed as above.
FIGURE 8. p38 phosphorylates Ser-34 and -217 of Dlx5. A, HEK-293 cells
transfected with the indicated constructs were labeled with [35S]methi-
onine for 3 h as described under “Experimental Procedures.” Immunopre-
cipitated Dlx5s were visualized by SDS-PAGE and autoradiography. wt,
wild type. B, wild type and mutated GST-Dlx5 fusion proteins were incu-
bated with activated p38 MAPK in presence of -[32P]ATP and visualized
by either SDS-PAGE and autoradiography or immunoblotting (WB) against
Dlx5. C and D, C2C12 cells were cotransfected with the indicated con-
structs. Cells were grown to confluence and either serum-starved (C) or
serum-starved and treated with BMP-2 for 16 –20 h (D). Luciferase activi-
ties are expressed as the mean  S.E. for triplicates from five independent
experiments after normalization with -galactosidase activity. E, C2C12
cells transfected with the indicated constructs were grown to confluence,
serum-starved overnight, and treated with BMP-2 for 8 h. Relative values
of Osx mRNA expression were obtained by RT-qPCR and expressed as the
mean  S.E. from four independent experiments after normalization by
GAPDH expression.
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genes, Runx2-II and Osx. Then, Dlx5 acting together with
either Runx2-II and/or Osx, would ensure an efficient activa-
tion of late osteogenic gene products. This functional cooper-
ativity has been demonstrated in the promoter of bone sialo-
protein where Runx2 and Dlx5 bind to adjacent sites and
physically interact to drive full promoter activation (45). Simi-
larly, it has been shown that both Dlx5 andOsx are required for
osteoblast-specific expression of type I collagen and osteocalcin
(8, 11, 20, 46), although the precise mechanisms of such coop-
erativity are still unknown.
BMPs up-regulate the expression of several homeodomain
transcription factors critical for osteoblast differentiation such
as Dlx5, Dlx3, or Msx2 (4, 21). These homeodomain transcrip-
tion factors exhibit distinct temporal expression profiles
during osteoblast differentiation: Msx2 expressed in the pro-
liferative state, Dlx3 expressed in osteoprogenitors, and Dlx5
expressed in more mature osteoblasts. This fact and the
selective association of these factors at different promoters
lead to the hypothesis that a hierarchy of multiple homeodo-
main transcription factors constitutes a network that control
the progression of osteoblast differentiation and maturation
(20, 21, 23). Here we show that Dlx3, also up-regulated by
BMP-2, does not elicit a strong transcriptional activation of
Osx reporter construct (Fig. 3). Thus, our data fit with this
scenario where Dlx5, which is induced after osteogenic com-
mitment in C2C12 as well as primary calvarial osteoblasts
(21), is the main activator of the late osteogenic master gene
Osx.
p38 MAPK is known to play an
important role in stress response
and cell differentiation (47). The
phosphorylation and activation of
p38 occurs soon after BMP stimula-
tion through an Smad-independent
pathway (for review, see Ref. 37).
Previous studies have shown that
p38 activation is clearly involved in
several steps of the osteoblast line-
age progression, necessary but not
sufficient for the BMP-induced
acquisition of the osteoblast pheno-
type (38). It has been suggested that
the p38 signaling may initially up-
regulate early markers such as alka-
line phosphatase but directly or
indirectly suppress late markers
such as osteocalcin (30, 40, 48). Sev-
eral lines of evidence also indicate
that p38 activity modulates Osx
expression induced by BMP in cal-
varial as well as bone marrow-de-
rived mesenchymal stem cells (30,
41, 43). Here we provide a mecha-
nism by which p38 could activate
Osx expression through direct
phosphorylation of Dlx5 in Ser-34
and Ser-217. First, activated recom-
binant p38 phosphorylates Dlx5 in
vitro, whereas the Dlx5(S34A/S217A) mutant shows a much
lower in vitro and in vivo phosphorylation. Second, phospho-
rylation of Dlx5 is induced by the addition of BMP-2 or the
expression of constitutive active MKK6, whereas it is blocked
by the pharmacological inhibition of p38. Moreover, p38-me-
diated phosphorylation of Dlx5 appears to act primarily at the
level of its transactivation function. Indeed, a constitutive active
MKK6 increases endogenous Osx expression and activates
Dlx5-driven Osx promoter activity through a homeobox bind-
ing site. Additionally, a constitutively active MKK6 enhances
the transcriptional ability of wild type but not of Dlx5(S34A/
S217A). Thus, we propose a regulatory network where BMP
activates the expression of Osx through the Dlx5 induction and
its further transcriptional activation by p38-mediated phos-
phorylation (Fig. 9). Our results do not exclude the possibility
that other transcription factors involved inOsx expressionmay
also serve as p38 substrates. In fact, the phosphorylation sites
found in Dlx5 are well conserved in other Dlx members such as
Dlx3 or Dlx6.
Acetylation of histones in chromatin is commonly associated
with transcriptionally active genes, and p300 and histone
deacetylases (HDACs) have been shown to bind and regulate
the acetylation of the core histones H3 andH4 in several osteo-
genic gene promoters. For instance, p300 is recruited to the
osteocalcin promoter in response to osteogenic signals (46, 49),
or JunB recruits p300 to activate dentin matrix protein 1 (50),
whereas HDAC4 inhibits Runx2 activity and HDAC4 null mice
exhibit strong skeletal defects (51). BMPs have been shown to
FIGURE 9. Model of a novel activation mechanism of Dlx5 by BMP-2. Activation of the BMP signaling
pathway leads to increased levels of Dlx5 through the activation of its promoter. In addition activation of p38
by BMP-2 leads to enhanced transcriptional activity of Dlx5 through increased interaction with p300 or addi-
tional transcriptional regulators (X).
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switch recruitment fromHDAC1 to p300 in osteocalcin or Osx
gene promoters and to promote hypomethylation of CpG sites
in Dlx5 and Osx promoter regions (46, 52). Similarly, BMPs
have been shown to increase the expression and function of the
ATP-dependent chromatin-remodeling complex SWI/SNF,
which has been shown to be absolutely required for osteogen-
esis (53, 54). Our study has demonstrated that p300 is
recruited by Dlx5 to the Osx proximal promoter and p300
histone acetyltransferase activity is involved in Dlx5-in-
duced activation of Osx transcription. This evidence would
be in agreement with data showing that p53 inhibits osteo-
genesis and Osx expression by impeding p300 from binding
to the proximal region of the Osx promoter where Dlx5
binds (31) and the minor requirement of p38 activity to
BMP-induced activation of Osx expression in p53-deficient
osteoblasts (43). Thus, it could be hypothesized that phos-
phorylation by p38 increases the ability of Dlx5 to recruit
other DNA binding transcription factors or coactivators
such as p300 and/or SWI/SNF as has been shown for p38-
dependent JunB recruitment of p300 on dentin matrix pro-
tein 1 promoter or p38-dependent activation of MyoD and
MEF2 in muscle-specific genes (47, 50).
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